Effect of TTP488 in patients with mild to moderate Alzheimer's disease.
about
Advances in Alzheimer's disease drug developmentSoluble RAGE Treatment Delays Progression of Amyotrophic Lateral Sclerosis in SOD1 Mice.Regulation of RAGE splicing by hnRNP A1 and Tra2β-1 and its potential role in AD pathogenesisReceptor for advanced glycation endproduct modulators: a new therapeutic target in Alzheimer's disease.New therapeutic approaches for Alzheimer's disease and cerebral amyloid angiopathy.Neurovascular dysfunction and neurodegeneration in dementia and Alzheimer's diseaseTherapeutic approaches to diabetic nephropathy--beyond the RAS.Circulating soluble receptor for advanced glycation end products (sRAGE) as a biomarker of emphysema and the RAGE axis in the lung.The role of S100 proteins and their receptor RAGE in pancreatic cancer.Targeting the Receptor for Advanced Glycation Endproducts (RAGE): A Medicinal Chemistry Perspective.Cellular mechanisms and consequences of glycation in atherosclerosis and obesity.Glycation & the RAGE axis: targeting signal transduction through DIAPH1.All the "RAGE" in lung disease: The receptor for advanced glycation endproducts (RAGE) is a major mediator of pulmonary inflammatory responses.Amyloid beta: structure, biology and structure-based therapeutic development.Targeting neuroinflammation in Alzheimer's disease: evidence for NSAIDs and novel therapeutics.The role of amyloid beta clearance in cerebral amyloid angiopathy: more potential therapeutic targets.Synthesis and Evaluation of [(18)F]RAGER: A First Generation Small-Molecule PET Radioligand Targeting the Receptor for Advanced Glycation Endproducts.Recent Progress in the Pharmacotherapy of Alzheimer's Disease.Detection of the receptor for advanced glycation endproducts in neuronally-derived exosomes in plasma.
P2860
Q26849352-ABA93B04-934B-4EB2-B5E9-5FD5D20ED5E4Q27319831-9D094C93-B5F5-4288-9540-CD946D0D4A99Q28910474-B0AC8C67-3215-4D3B-B56E-FDB07083CC05Q33887359-55A0DE86-A253-4B09-B603-1F124266392AQ34368970-A0D8DCB7-BE08-436A-B542-57D678660913Q36767796-18D38472-C90F-4925-BB12-B688F7D3B624Q38209811-B952821D-F672-4564-95BC-B1F394E23A3AQ38541559-2CF5B399-DF93-46CF-B7E0-BEF09AE636A7Q38598852-EC7192A9-54E8-4781-AFBB-66568D58AAD4Q38686477-AC1A2AD9-FB48-4ADF-B0CE-F8624866562BQ38831558-087E7B3D-6846-4793-9228-826041B36D0CQ39038218-94FC5FED-FCD8-4F22-8411-DAC63C8ADE86Q39246681-5462B966-BE97-4793-89E9-733EDC2AE9B3Q39437881-767B1852-6FE4-40F9-A4D4-51D2E3746059Q39689655-725AD768-0A6E-4E44-8568-B55938BFAECBQ41439008-12B8048B-B112-4DF6-8CF6-CB0313DDCD0FQ47118949-4A930AD9-94C5-472F-8CAF-9822C31583FEQ47425364-01CA7389-0083-4325-9BBC-49A89ABF579BQ52558831-F273903C-3B78-465D-B26D-16F53323D535
P2860
Effect of TTP488 in patients with mild to moderate Alzheimer's disease.
description
2014 nî lūn-bûn
@nan
2014 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Effect of TTP488 in patients with mild to moderate Alzheimer's disease.
@ast
Effect of TTP488 in patients with mild to moderate Alzheimer's disease.
@en
type
label
Effect of TTP488 in patients with mild to moderate Alzheimer's disease.
@ast
Effect of TTP488 in patients with mild to moderate Alzheimer's disease.
@en
prefLabel
Effect of TTP488 in patients with mild to moderate Alzheimer's disease.
@ast
Effect of TTP488 in patients with mild to moderate Alzheimer's disease.
@en
P2093
P2860
P356
P1433
P1476
Effect of TTP488 in patients with mild to moderate Alzheimer's disease.
@en
P2093
Aaron H Burstein
Adnan M M Mjalli
Douglas R Galasko
Imogene Grimes
Marwan Sabbagh
P2860
P2888
P356
10.1186/1471-2377-14-12
P577
2014-01-15T00:00:00Z
P5875
P6179
1008037831